AddedRisk Factors
There remains substantial uncertainty as to how the current U.S. administration will seek to or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over VYJUVEK and our
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedRisk Factors
European Commission, MHLW, or other foreign regulators may issue new or revised guidelines concerning the development and marketing authorization of gene therapy medicinal products.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedRisk Factors
We were granted RMAT designation for B-VEC from the FDA, and we may seek RMAT designation for some of our product candidates. In 2017, the FDA established the RMAT designation as part of its implementation of the 21st Century Cures Act to expedite review of any drug that meets the following criteria: it qualifies as a RMAT, which is defined as a cell
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedRisk Factors
•identification of patients and the willingness of physicians to prescribe new therapies;
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RemovedRisk Factors
become subject to equitable remedies that could materially and adversely affect our operations and financial results. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2032 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers, and increased the time for Medicare contractors to recoup Medicare overpayments to providers from three to five years.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
At this time, we continue to evaluate the effect of the IRA on our business operations and financial condition and results as the full impact of the IRA remains uncertain.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
addressed, may harm our reputation, damage our brand, and erode trust. Our systems, and those of any third-party with whom we do business, may also be vulnerable to software viruses, stolen, misplaced, or lost data, programming and/or human errors, or other similar events which may disrupt our operations or expose personal and confidential information.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Additionally, the use of AI solutions by us or third parties on which we rely could lead to (i) the public disclosure of confidential information (including personal data of our employees, clinical trial participants, or other third parties) in
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Increased attention to, and evolving expectations for, environmental, social, and governance (“ESG”) initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Companies across industries are facing increasing scrutiny from a variety of stakeholders related to their ESG, including diversity, equity, and inclusion (“DEI”), and sustainability practices. Investor advocacy groups, certain institutional investors, investment funds, and other influential investors have increasingly focused on ESG practices and have placed increasing importance on the non-financial impacts of their investments. Expectations regarding voluntary ESG initiatives and disclosures may result in increased costs (including but not limited to increased costs related to compliance, stakeholder engagement, contracting, and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results of operations.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) to improve the ESG profile of our company and/or VYJUVEK and our product candidates, such initiatives may be costly and may not have the desired effect. Moreover, we may not be able to successfully complete such voluntary initiatives due to factors that are within or outside of our control. Even if this is not the case, our actions may subsequently be determined
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently voluntary.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Certain market participants, including major institutional investors and capital providers, use third-party benchmarks and scores to assess companies’ ESG profiles in making investment or voting decisions. Unfavorable ESG ratings could lead to increased negative investor sentiment towards us or our industry, which could negatively impact the price of our common stock. In addition, in recent years “anti-ESG” sentiment has gained momentum across the United States, with several states and Congress having proposed or enacted “anti-ESG” policies, legislation, or initiatives or issued related legal opinions, and the President having recently issued an executive order opposing DEI initiatives in the private sector. Such anti-ESG and anti-DEI-related policies, legislation, initiatives, litigation, legal opinions, and scrutiny could result in us facing additional compliance obligations, becoming the subject of investigations and enforcement actions, or sustaining reputational harm. Therefore, to the extent we take actions that are seen as positive to some investors, other investors may take issue with such actions or face regulatory pressure to refrain from investing in, or divest from, our business. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees, customers, or business partners which may adversely impact our operations.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, there may be increasing levels of regulation, disclosure-related and otherwise, with respect to ESG matters. For example, the SEC recently adopted new rules that require companies to provide significantly expanded climate-related disclosures in their periodic reporting. The new climate disclosure rules were the subject of multiple legal challenges, and the SEC voluntarily stayed the climate disclosure rules pending the completion of judicial review. Therefore, it is unknown whether the new rules will go into effect and if they do, whether there will be significant changes. If the new rules go into effect and are not substantially different than the rules adopted by the SEC, we may be required to incur significant additional costs to comply, including the implementation of significant additional internal controls processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors. Even if the SEC rules are not adopted, states or ex-U.S. jurisdictions in which we currently or may in the future operate may also have or adopt ESG or climate-related disclosure rules requiring similar or broader disclosure obligations. These and other changes in stakeholder expectations will likely lead to increased costs as well as scrutiny that could heighten all of the risks identified in this risk factor. Additionally, our customers and suppliers may be subject to similar expectations, which may augment or create additional risks, including risks that may not be known to us.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RewordedRisk Factors
If the models underlying AI technologies that we use or may use are incorrectly designed designed, implemented, or implemented, trained, or reliant trained; rely on incomplete, inadequate, inaccurate, biased, or otherwise poor quality data, or poor-quality data; rely on data with respect to which we do not have sufficient rights or in relation to for which we and/or or the data providers of such data have not implemented sufficient appropriate legal compliance measures, measures; are used without sufficient oversight and governance to ensure their responsible use, use; are misused, or used outside of the scope of applicable regulatory authorizations, and/or authorizations; or are adversely impacted by unforeseen defects, technical challenges, cybersecurity threats, or material performance issues, the performance of our products and business, as well as our reputation, could suffer or we could incur liability resulting from the violation of laws or contracts to which we are a party, regulatory enforcement actions, or civil claims. suffer.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our use of distributors in these markets to market and sell VYJUVEK involves certain risks, including, but not limited to, risks that these organizations will not comply with applicable laws and regulations, not effectively sell or support VYJUVEK or reduce or discontinue their efforts to sell or support VYJUVEK, not devote the resources necessary to market and sell VYJUVEK in the volumes and within the time frame we expect, not be able to satisfy financial obligations to us or others, not provide us with accurate or timely information regarding their inventories of VYJUVEK or the number of patients who are using VYJUVEK, or not provide us with accurate or timely information regarding serious adverse events and/or product complaints.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the EU General Data Protection Regulation (“GDPR”) and UK GDPR impose strict requirements for processing personal information, and companies Companies that violate the GDPR may face temporary or permanent bans on certain data processing activities and they may be subject to other penalties such as significant penalties, including fines of up to 20 million Euros under the EU GDPR / or 17.5 million pounds sterling under the UK GDPR GDPR, or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal information brought by classes of data subjects or consumer protection organizations authorized to represent data subjects’ interests. greater.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any dispute, claim, or lawsuit may divert management’s attention away from our business, we may incur result in significant expenses in addressing to address or defending any dispute, claim, or lawsuit, defend such matters, and we may be required require us to pay damage awards or settlements or become subject to equitable remedies, any of which could materially and adversely affect our operations and financial results.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, if we experience delays in obtaining approval, or if we fail to obtain approval of our product candidates, we may lose any marketing approval that we may have obtained, which would materially and adversely affect our business, financial condition, results of operations, and prospects. prospects, or the commercial prospects for our product candidates may be harmed and our ability to generate revenue could be materially impaired.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even though we have obtained orphan drug exclusivity for VYJUVEK in the United States; States, EU, and Japan and obtained orphan drug designation for B-VEC in the European Union and Japan; orphan drug designation for KB105 and KB407 certain product candidates in the United States and the European Union; and orphan drug designation for KB408 in the United States, Union, we may not be able to maintain orphan drug exclusivity, and if we are able to maintain the orphan drug exclusivity, the exclusivity may not effectively protect the product or product candidate from competition because different drugs can be approved for the same condition.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are required by the FDA, the EMA, the PMDA, European Commission, the MHLW, or other regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of our product candidates, our expenses could increase and the timing or amount of revenue from product candidates in development could be adversely affected.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan designation, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Provisions in our corporate charter documents certificate of incorporation and under bylaws, as well as provisions of Delaware law law, could make an acquisition of us, which our company that may be beneficial to our stockholders, stockholders more difficult and may could prevent attempts by or deter our stockholders to replace from replacing or remove removing our current management.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we received approval from Food and Drug Administration, or FDA, the FDA European Commission, and Japan’s Ministry of Health, Labour and Welfare, or MHLW, for VYJUVEK for the treatment of dystrophic epidermolysis bullosa, or DEB, we can provide no assurances that we will obtain regulatory approval in any other jurisdiction, which would could have an adverse impact on our results of operations.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we or the third parties that process personal information or other sensitive data on our behalf fail, or are perceived to have failed, to address or comply with applicable privacy and data security obligations, we could face significant consequences, including but not limited to government enforcement actions (e.g., investigations, fines, penalties, audits, and inspections), litigation (including class-action claims), additional reporting requirements and/or oversight, bans on processing personal information, and orders to destroy or not use personal information.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
We received FDA approval of VYJUVEK in May 2023 2023, European Commission approval of VYJUVEK in April 2025, and MHLW approval in July 2025, and initiated a commercial launch of VYJUVEK in the United States in the second quarter of 2023. 2023, in Germany in August 2025, and in Japan in October 2025.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
There is also a risk of inappropriate disclosure of sensitive information, loss of trade secrets or other intellectual property, public exposure of personal information of our employees, patients who use VYJUVEK, clinical trial patients, and others, or negative or inaccurate posts or comments about us on any social networking website. media.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Further, the cost to comply with such laws, regulations or decisions and/or guidance interpreting existing laws, could be significant and would could increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI).
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We can could face criminal liability and other serious consequences for violations, which can could harm our business.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Any third parties conducting our preclinical studies or our clinical trials will are not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical programs.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
A loss of key personnel or their work product could hamper or prevent our ability to commercialize VYJUVEK or our product candidates, if approved, which could have an adverse effect on our business, results of operations, and financial condition.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our Chief Executive Officer and Chairman of the Board of Directors and our Founder, President, Research & Development and Director will have the ability to substantially influence all matters submitted to stockholders for approval.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
VYJUVEK is a non-invasive, topical, redosable gene therapy approved in the United States, Europe, and Japan for the treatment of DEB, a rare and severe monogenic disease that affects the skin and mucosal tissues and is caused by one or more mutations in a gene called COL7A1. VYJUVEK is designed to deliver two copies of the COL7A1 gene when applied directly to DEB wounds, providing the patient’s skin cells the template to make normal type VII collagen protein and thereby addressing the fundamental disease-causing mechanism.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
We are commercializing VYJUVEK directly in the United States, major European markets, and Japan. We launched VYJUVEK in the United States in 2023, in Germany in August 2025, and in France and Japan in October 2025. The launch in France is under the post-marketing authorization early reimbursed access Accès Précoce program.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
Pricing negotiations are underway in both Germany and France and are expected to continue until at least the second half of 2026 in Germany and 2027 in France. Pricing negotiations were successfully completed in Japan prior to launch.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
We are advancing pricing discussions with Italian reimbursement authorities to enable a potential launch in Italy in the second half of 2026. We are also preparing regulatory filings for the United Kingdom and Switzerland, as well as initiating pricing discussions with relevant authorities in other key Western European markets. The timing of additional European launches will depend on the cadence and outcomes of regulatory interaction and pricing negotiations.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
We continue to expand our specialty distributor network to support the commercialization of VYJUVEK in territories outside of the United States, major European markets, and Japan.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
KB801 is an eye drop formulation of our novel HSV-1 based vector designed to deliver two transgene copies to the corneal epithelium for the sustained, localized expression and secretion of nerve growth factor and the treatment of NK, a rare, degenerative corneal disease caused by nerve damage in the eye that leads to corneal epithelial defects, ulcers, and perforation. Our engineered HSV-1 viral vector used in KB801 was granted platform technology designation by the FDA in October 2025. We are currently running a registrational, randomized, double-masked, multicenter, placebo-controlled study, EMERALD-1, evaluating KB801 for the treatment of NK. We expect to enroll approximately 60 adult patients with Stage 2 or Stage 3 NK in EMERALD-1. Enrollment is ongoing, and we expect to report top-line data in 2026.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
KB707 is a redosable, cancer immunotherapy designed to deliver genes encoding both human interleukin-2 and interleukin-12 to the tumor microenvironment and promote systemic immune-mediated tumor clearance. Two formulations of KB707 are in development, a solution formulation for transcutaneous injection and an inhaled (nebulized) formulation for lung delivery. We have prioritized development of the inhaled KB707 formulation for the treatment of non-small cell lung cancer (“NSCLC”) based on early evidence of efficacy from KYANITE-1, our ongoing, Phase 1/2 study evaluating inhaled KB707, as monotherapy or in combination to treat patients with locally advanced or metastatic solid tumors of the lung. We opened a new cohort in KYANITE-1 in late 2025 to evaluate inhaled KB707 in combination with chemotherapy in patients with advanced NSCLC. Enrollment in this cohort is ongoing, and we expect to report interim efficacy data and potential registrational study plans in 2026.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
We continue to follow patients enrolled in OPAL-1, our Phase 1/2 study, evaluating intratumoral KB707, as monotherapy or in combination, for the treatment of locally advanced or metastatic solid tumors.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
In addition to focusing on genetic medicines to treat patients with diseases with high unmet medical needs, we are leveraging the ability of our platform to deliver proteins of interest to cells in the skin in the context of aesthetic medicine via our wholly-owned subsidiary, Jeune Aesthetics. Based on the broad aesthetic improvements observed following KB304 treatment in PEARL-2, our Phase 1 study evaluating KB304 for the treatment of wrinkles of the décolleté, we are progressing KB304 into Phase 2 study for the treatment of wrinkles of the décolleté. We have aligned with the FDA on our validated décolleté-specific photonumeric scale, and we now expect to initiate the Phase 2 study in 2027.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
Jeune Aesthetics has several other aesthetic medicine product candidates in various stages of development, including our clinical-stage product candidate KB301 that is designed to deliver two copies of the COL3A1 transgene for the treatment of aesthetic skin conditions. We are currently evaluating aesthetic indications most suitable for advanced clinical development of KB301.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
The Company is subject to tax in the United States and numerous foreign jurisdictions. Significant judgments and estimates are required in the determination of consolidated income tax expense. Income tax expense reflects the Company’s best estimate of current and future taxes to be paid. The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. The Company weighs all available evidence, including cumulative income and forecasted future income in order to assess the realizability of deferred tax assets. The assumptions about future taxable income require the use of significant judgment and are consistent with the plans and estimates the Company is using to manage the underlying business. In the event the Company determines that it will be able to realize deferred tax assets for which a valuation allowance was used to reduce their carrying value, the adjustment to the valuation allowance will be recorded as a reduction to the provision for income taxes in the period such determination is made.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across global operations. Significant judgment is required in the identification and measurement of uncertain tax positions. The liability for unrecognized tax benefits contains uncertainties because the Company is required to make assumptions and to apply judgment to estimate the exposures associated with our various filing positions. The Company adjusts the liabilities when judgment changes as a result of new information not previously available.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RemovedMD&A
VYJUVEK (beremagene geperpavec-svdt or B-VEC; referred to as B-VEC outside the United States)
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
On May 19, 2023, the FDA approved VYJUVEK, the first ever redosable gene therapy, for treating patients, six months of age or older, suffering from DEB, a rare and severe monogenic disease that affects the skin and mucosal tissues and is caused by one or more mutations in a gene called COL7A1. VYJUVEK is a redosable topical gel containing our novel vector designed to deliver two copies of the COL7A1 transgene to a patient’s skin cells to produce the COL7 protein. VYJUVEK is the first and only corrective medicine approved by the FDA for the treatment of DEB, both recessive and dominant, that can be administered by a healthcare professional in either a clinical setting or in the home. We possess exclusive rights to develop, manufacture, and commercialize VYJUVEK and all our pipeline product candidates throughout the world.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We have secured strong nationwide access and reimbursement for VYJUVEK in the United States since launch and, as of February 2025, positive access determinations have been achieved for 97% of lives covered under commercial and Medicaid plans. In January 2024, we announced that the United States Centers for Medicare & Medicaid Services, or CMS, had assigned a permanent and product-specific J-code for VYJUVEK, effective on January 1, 2024.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
As of February 2025, we have secured over 510 reimbursement approvals for VYJUVEK in the United States.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We seek to make the experience of starting and continuing on VYJUVEK treatment seamless for the patient. Since launch, the infrastructure has been in place for patients to be treated in their home by a healthcare professional, reducing the need for regular visits to a clinic or hospital. Krystal ConnectTM, our United States in-house patient services call center, has been active since FDA approval and assists patients, caregivers and healthcare professionals interested in accessing VYJUVEK. Since launch and through the fourth quarter of 2024, patient compliance with once weekly treatment while on VYJUVEK remains high at 85%.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
Preparations and infrastructure buildout are underway in Europe and Japan to support our planned direct commercial launch in these regions in 2025.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
In October 2023, we submitted a MAA to the EMA for B-VEC for the treatment of DEB. In February 2024, the EMA completed inspection of our manufacturing facility as part of the MAA review process and, in May 2024, EU GMP certification was granted by the EMA. EMA review of our MAA is ongoing and we currently expect a CHMP opinion the first quarter of 2025.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
In September 2024, the Haute Autorité de Santé in France approved pre-marketing early reimbursed access to B-VEC under the Accès Précoce (“AP1”) program. AP1 allows for early access to innovative therapies in France prior to European regulatory approval when a positive benefit/risk ratio is recognized and when no other therapeutic alternatives are available.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
In October 2024, we filed a JNDA with Japan’s PMDA. The JNDA includes the results from the Japan OLE study, the design of which had been approved by the PMDA in July 2023. The efficacy portion of the Japan OLE study was completed in April 2024 and results closely mirrored those of our Phase 3 study in the United States, with B-VEC exhibiting a safety profile consistent with previous studies and all four patients that completed the study achieving the primary endpoint of complete wound closure at six months. The JNDA is under priority review and a decision by the PMDA is expected in the second half of 2025.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
Based on early clinical evidence of safety and potential benefit following topical B-VEC application to the eye of a DEB patient under compassionate use, we started discussions with the FDA on a potential clinical development path for KB803 and, in February 2024, we aligned with the FDA on our proposed single arm, open label registrational Phase 3 study to enable approval of KB803 to treat ocular complications of DEB. We expect to initiate the study in the first half of 2025 and plan to enroll up to 30 DEB patients.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
In August 2024, we initiated a natural history study to prospectively collect data on the frequency of corneal abrasions in patients with DEB and serve as a run-in period for patients who may be eligible to participate in the Phase 3 study. Enrollment in the study is ongoing and, as of February 2025, we had enrolled approximately 50 patients in the study.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We are also actively evaluating multiple, internal preclinical-stage genetic medicine candidates for the treatment of front and back of the eye diseases.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RewordedMD&A
KB105 KB111 is a topical gel containing formulation of our novel vector designed to deliver two copies of the TGM1 ATP2C1 transgene encoding the human enzyme TGM1 calcium transporter ATPase type 2C member 1 (“ATP2C1”) for the treatment of TGM1-deficient LI, HHD, a serious and rare monogenic skin disorder most often caused characterized by missing or mutated TGM1 protein. painful rash and blistering in skin folds and linked to low ATP2C1 expression levels in keratinocytes.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
In February 2024, we announced that we had dosed the first patient in SERPENTINE-1, We are currently running a a Phase 1, open-label, single dose escalation study 1 study, SERPENTINE-1, evaluating KB408, delivered via a nebulizer, KB408 for the treatment of AATD in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities for the year ended December 31, 2023 2025 was $202.8 $8.7 million and consisted of proceeds of $159.7 million from issuances of common stock, net of offering costs and proceeds of $43.8 $22.7 million from exercises of stock options, partially offset by $749 thousand $12.1 million used for employee tax withholding payments related to vested restricted stock units and $1.8 million used for employee tax withholding payments for settlement of vested restricted stock awards.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
In July 2023, January 2026, we announced that we had dosed a positive interim clinical update from Cohort 3, the first patient in highest dose cohort of CORAL-1, a our Phase 1 multi-center, dose-escalation study evaluating KB407, delivered via a nebulizer, in KB407 for the treatment of patients with CF, regardless of their underlying genotype.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Product revenue, net was $389.1 million for the year ended December 31, 2025 as compared to $290.5 million for the year ended December 31, 2024 as compared to and $50.7 million for the year ended December 31, 2023 and zero for the year ended December 31, 2022 due to initial sales of VYJUVEK after FDA approval was obtained on May 19, 2023.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
(1)Unallocated manufacturing (1)Other unallocated expenses consist of shared pre-commercial manufacturing costs, primarily relating to certain raw materials, contract manufacturing, contract testing, process development, quality control and quality assurance activities and activities, as well as other manufacturing and facility related costs including rent, storage and depreciation which support the development of multiple product candidates in our preclinical and clinical development programs. candidates.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cost of goods sold from 2023 2024 to 2024 2025 was driven by an increase in VYJUVEK sales following initial commercial sales recorded partially offset by a decrease primarily due to manufacturing process optimizations that resulted in August 2023. lower average costs per unit.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
As we seek to obtain regulatory approval for our product candidates, candidates and prepare for product sales, marketing, commercial manufacturing, packaging, labeling and distribution, we expect to continue to incur significant manufacturing and commercialization expenses as we prepare for product sales, marketing, commercial manufacturing, packaging, labeling and distribution. expenses.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The estimated remaining commitment as of December 31, 2024 under these agreements is approximately $627 thousand, all of which is expected to be due in the next twelve months. months as of December 31, 2025 under these agreements is immaterial.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Non-cash adjustments included depreciation of $6.0 $5.7 million, amortization of operating lease right-of-use assets of $747 thousand, $0.8 million, stock-based compensation expense, net of $49.1 $54.5 million, and other adjustments of $652 thousand offset by realized gain on investments of $6.1 million and accretion on marketable securities of $1.7 million.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of goods sold was $23.0 million for the year ended December 31, 2025 as compared to $20.1 million for the year ended December 31, 2024 as compared to and $3.1 million for the year ended December 31, 2023 and zero for the year ended December 31, 2022 due to initial sales of VYJUVEK after FDA approval was obtained on May 19, 2023.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Interest and other income, net for the years ended December 31, 2024, 2025, 2024 and 2023 and 2022 was $29.7 $28.2 million, $22.6 $29.6 million and $5.2 $22.5 million, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. investments as well as the effects of foreign exchange rates.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesMD&A
The risks and uncertainties can cause actual results to differ significantly materially from those forecast in forward-looking statements or implied in historical results and trends.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new